The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Induction chemotherapy is often administered to induce complete remission (CR) in patients with acute myeloid leukemia, prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT). Many patients who do not achieve CR after the first induction course (IND1) will go on to achieve CR after a second induction course (IND2). However, outcomes of patients who achieved CR with IND1 vs IND2 have yet to be compared.
Here, we summarize the key results published by Loke et al.1 in Cancer from a registry-based study aiming to identify the prognostic value of the number of induction courses required to achieve CR, as well as which prognostic factors influence outcomes in patients requiring IND2 to achieve CR prior to allo-HSCT.
Figure 1. 5-year survival outcomes for patients requiring IND1 or IND2 to achieve CR prior to allo-HSCT*
Allo-HSCT, allogeneic hematopoietic stem cell transplant; CIR, cumulative incidence of relapse; IND1, one induction course; IND2, two induction course; OS, overall survival.
*Adapted from Loke, et al.1
Figure 2. Effect of MRD prior to allo-HSCT on 2-year OS for patients treated with IND1 or IND2*
Allo-HSCT, allogeneic hematopoietic stem cell transplant; IND1, one induction course; IND2, two induction courses; MRD, measurable residual disease; OS, overall survival.
*Adapted from Loke, et al.1
Key learnings |
|
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content